Featured Posts
Study
A Free Market is the Best Medicine
Introduction The pharmaceutical supply market is seeing extraordinarily high levels of innovation and consumer-benefiting evolution. The combination of a competitive market for generic drugs, rapid…
Blog
Congress considers micromanaging PBM finances
With the first reconciliation bill behind it, Congress is now looking to reform other aspects of the health care system. Pharmacy Benefit Manager (PBM)…
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…
Search Posts
Study
EPA’s Flawed IRIS Program Is Far from Gold Standard
Environmental activists claim that the U.S. Environmental Protection Agency’s Integrated Risk Information System (IRIS) represents the gold standard for risk assessment.[i] In…
Products
Free to Prosper: Food, Drugs, and Consumer Freedom
View the full chapter on food, drugs, and consumer freedom here Few matters are as important to consumers as the foods they eat, the…
Blog
One Year Later, Federal Plan on Tobacco Harm Reduction Needs Improvement
The Food and Drug Administration has failed to approve a single reduced-harm nicotine product in the past year, despite unveiling a new “roadmap” in…
Blog
Growing Human Organs for Fun and Profit
Our friends at Freethink Media have an excellent new video out about medical innovation—in this case, how a new company is developing…
The Washington Examiner
Trump Keeps His Promise, Dying Patients Get a Second Chance At Life
The Washington Examiner cited the Competitive Enterprise Institute on the direct toll to human life that regulations impose as a result of ever-increasing FDA clinical…
The Hill
‘Right to Try’ Is a Win for Patient Rights and President Trump
The Hill cited the Competitive Enterprise Institute on the overwhelming cost of compliance which taxes the American economy and in this case limits pharmaceutical ingenuity…